Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence
Background Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic
spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias …
spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias …
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1
M Maurer, K Weller, C Bindslev‐Jensen… - Allergy, 2011 - Wiley Online Library
To cite this article: Maurer M, Weller K, Bindslev‐Jensen C, Giménez‐Arnau A, Bousquet PJ,
Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M …
Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M …
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
This update and revision of the international guideline for urticaria was developed following
the methods recommended by Cochrane and the Grading of Recommendations …
the methods recommended by Cochrane and the Grading of Recommendations …
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
This evidence‐and consensus‐based guideline was developed following the methods
recommended by Cochrane and the Grading of Recommendations Assessment …
recommended by Cochrane and the Grading of Recommendations Assessment …
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
This guideline is the result of a systematic literature review using the 'G rading of R
ecommendations A ssessment, D evelopment and E valuation'(GRADE) methodology and a …
ecommendations A ssessment, D evelopment and E valuation'(GRADE) methodology and a …
The burden of chronic spontaneous urticaria is substantial: real‐world evidence from ASSURE‐CSU
Background Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and
frustrating for patients and physicians. Real‐world evidence for the burden of CSU is limited …
frustrating for patients and physicians. Real‐world evidence for the burden of CSU is limited …
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Background Many patients with chronic idiopathic urticaria (also called chronic spontaneous
urticaria) do not have a response to therapy with H1-antihistamines, even at high doses. In …
urticaria) do not have a response to therapy with H1-antihistamines, even at high doses. In …
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the H ereditary A ngioedema I nternational W orking G roup
Angioedema is defined as localized and self‐limiting edema of the subcutaneous and
submucosal tissue, due to a temporary increase in vascular permeability caused by the …
submucosal tissue, due to a temporary increase in vascular permeability caused by the …
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
A Kaplan, D Ledford, M Ashby, J Canvin… - Journal of Allergy and …, 2013 - Elsevier
Background Patients with chronic idiopathic urticaria/chronic spontaneous urticaria
(CIU/CSU) often continue to experience symptoms despite receiving standard-of-care …
(CIU/CSU) often continue to experience symptoms despite receiving standard-of-care …
[HTML][HTML] Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized …
ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate
the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in …
the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in …